Online citations, reference lists, and bibliographies.
← Back to Search

Prognosis And Prognostic Factors Of Patients With Mesothelioma: A Population-based Study

S. van der Bij, H. Koffijberg, J. Burgers, P. Baas, M. J. van de Vijver, B. D. de Mol, K. Moons
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background:It is important to regularly update survival estimates of patients with malignant mesothelioma as prognosis may vary according to epidemiologic factors and diagnostic and therapeutic management.Methods:We assessed overall (baseline) survival as well as related prognostic variables in a large cohort of 1353 patients with a confirmed diagnosis of malignant mesothelioma between 2005 and 2008.Results:About 50% of the patients were 70 years or older at diagnosis and the median latency time since start of asbestos exposure was 49 years. One year after diagnosis, 47% of the patients were alive, 20% after 2 years and 15% after 3 years. Prognostic variables independently associated with worse survival were: older age (HR=1.04 per year 95% CI (1.03–1.06)), sarcomatoid subtype (HR=2.45 95% CI (2.06–2.90)) and non-pleural localisation (HR=1.67 95% CI (1.26–2.22)).Conclusion:Survival of patients with malignant mesothelioma is still limited and depends highly on patient age, mesothelioma subtype and localisation. In addition, a substantial part of the patients had a long latency time between asbestos exposure and diagnosis.
This paper references
10.1198/jasa.2003.s263
Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis
S. J. Rao (2003)
10.1016/J.JCLINEPI.2006.01.014
Review: a gentle introduction to imputation of missing values.
A. Donders (2006)
10.1097/JTO.0b013e3181f1cf2b
Malignant Pleural Mesothelioma: A Population-Based Study of Survival
M. Milano (2010)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1016/J.LUNGCAN.2004.04.012
Prognostic factors in malignant mesothelioma.
J. Burgers (2004)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
Prognostic factors and survival in malignant pleural mesothelioma.
T. van Gelder (1994)
10.1097/JTO.0b013e3181ba2033
Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma
Guntulu Ak (2009)
10.1289/ehp.11151
Asbestos Burden Predicts Survival in Pleural Mesothelioma
B. Christensen (2008)
10.1002/ijc.23866
Survival of peritoneal malignant mesothelioma in Italy: A population‐based study
D. Mirabelli (2009)
10.1093/ANNONC/MDL021
Occupational asbestos exposure: how to deal with suspected mesothelioma cases--the Dutch approach.
P. Baas (2006)
10.1097/00008469-199908000-00007
Increased but low incidence and poor survival of malignant mesothelioma in the southeastern part of The Netherlands since 1970: a population-based study.
M. Janssen-Heijnen (1999)
10.1002/IJC.2910410409
Survival patterns for malignant mesothelioma: The seer experience
R. Spirtas (1988)
10.1136/thx.2007.081430
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
Mesothelioma: a review.
F. Mott (2012)
10.1093/annonc/mdp307
Malignant peritoneal mesothelioma: a multicenter study on 81 cases.
V. Manzini (2010)
10.1136/bmj.b604
Prognosis and prognostic research: Developing a prognostic model
P. Royston (2009)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)



This paper is referenced by
Oncogenes and Tumor Suppressors Nonampli fi ed FGFR 1 Is a Growth Driver in Malignant Pleural Mesothelioma
L. Marek (2014)
10.1007/978-3-319-99510-6_4
Standardizing of Mesothelioma and Pseudomyxoma Care
Ranyell Spencer Sobreira Batista (2019)
10.1016/j.ejca.2015.07.033
Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study.
S. Francisci (2015)
10.1007/s00408-013-9516-y
Stratification of Malignant Pleural Mesothelioma Prognosis Using Recursive Partitioning Analysis
H. Suzuki (2013)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
10.4236/JCT.2017.85038
Malignant Pleural Mesothelioma in Young People
Ahmed El Bastawisy (2017)
10.1158/0008-5472.CAN-13-2062
Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
C. Menges (2014)
10.1111/1759-7714.13063
Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database
M. Zhuo (2019)
10.3892/ol.2016.4174
Simian virus 40 may be associated with developing malignant pleural mesothelioma
T. D. Thanh (2016)
Investigating heterogeneity of growth and drug response in mesotheliomas
Roxanne Otadoy (2013)
c-Met Axis − miR-34 a − Mesotheliomas with Enriched Cancer Stem Cells via a p 53 Tumor Suppressor Alterations Cooperate to Drive Aggressive
Craig W. Menges (2014)
10.1177/1753466620935770
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report
J. Hu (2020)
10.1186/s40064-016-1998-7
Clinical significance of serum CA125 in diffuse malignant mesothelioma
X. Cheng (2016)
10.1002/path.4377
Connective tissue growth factor and β‐catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma
L. Jiang (2014)
10.1158/1541-7786.MCR-14-0038
Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma
L. Marek (2014)
10.1007/s00268-017-4424-6
A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma
S. Wang (2017)
10.1007/s13665-013-0045-1
Prognostic factors for malignant pleural mesothelioma
F. Brims (2013)
10.1002/cam4.1378
Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis
C. Chouaid (2018)
10.1016/j.jtho.2016.06.024
A Phase II Study of PF‐03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207
P. Wheatley-Price (2016)
10.1016/j.cllc.2020.06.027
Mesothelioma Micronodular Metastasis Pattern Confirmed by Transbronchial Cryobiopsy: Case Report.
Jordy W Kerkhoff (2020)
Downregulation of miR-99 a / let-7 c / miR-125 b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma
A. Truini (2017)
10.1080/15287394.2020.1734891
MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma
Kyubo Kim (2020)
10.2147/OTT.S36915
Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival
P. Zarogoulidis (2012)
Stratification of Malignant Pleural Mesothelioma Prognosis Using
Hidekazu SuzukiKazuhiro (2014)
10.7759/cureus.3906
Malignant Peritoneal Mesothelioma Mimicking Recurrent Diverticulitis
Ernesto S Robalino Gonzaga (2019)
10.1016/j.jtho.2015.12.108
A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis
F. Brims (2016)
Asbestos and Toxicological Concerns
Gregory A. Cade (2019)
10.1136/oemed-2014-102614
Expected number of asbestos-related lung cancers in the Netherlands in the next two decades: a comparison of methods
S. van der Bij (2016)
10.1038/modpathol.2015.87
Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
J. Andrici (2015)
10.5301/tj.5000364
Sarcomatoid Mesothelioma: Future Advances in Diagnosis, Biomolecular Assessment, and Therapeutic Options in a Poor-Outcome Disease
D. Galetta (2016)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.3109/0284186X.2013.879609
Simultaneous acute myeloid leukemia and mesothelioma diagnoses in a long-term survivor of the 1984 Bhopal gas leak
J. Law (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar